

# HEALTHCARE MONTHLY

OCTOBER 2024

*Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.*








BioTech / Pharma

Healthcare Services

Life Sciences / Diagnostics


Medical Devices

## HEADLINE TRANSACTIONS


	TARGET	ACQUIROR	ACQUISITION SYNOPSISIS
BioTech / Pharma			<ul style="list-style-type: none"> <li>Organon &amp; Co. (NYSE: OGN) has entered a definitive agreement to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NASDAQ: ROIV)</li> <li>Organon is a pharmaceutical company operating in three business segments: Women's Health, Biosimilars and Established Medicines</li> <li>Dermavant Sciences develops and commercializes therapeutics in medical dermatology; its lead product candidate, Tapinarof, is a therapeutic targeting psoriasis and atopic dermatitis</li> <li>Roivant develops and commercializes therapeutics in immuno-dermatology</li> <li>Total Consideration: \$1.2 billion cash</li> </ul>
	<p>A Portfolio of CDK Inhibitors</p> 		<ul style="list-style-type: none"> <li>Genentech, a member of Roche Holding AG (SWX: ROG) has entered a definitive agreement to acquire a portfolio of CDK inhibitors from Regor Pharmaceuticals</li> <li>Regor Pharmaceuticals is a clinical-stage biotechnology company developing medicines in the oncology, metabolism and auto-immunity treatment areas</li> <li>Genentech offers pharmaceutical products that have applications in ophthalmology, metabolism and virology fields, including antibodies for cancer and medicine for primary progressive multiple sclerosis</li> <li>Roche develops oncology-focused pharmaceuticals and diagnostics products</li> <li>Total Consideration: \$850 million cash</li> </ul>
Life Sciences / Diagnostics			<ul style="list-style-type: none"> <li>Agilent Technologies, Inc. (NYSE: A) has entered a definitive agreement to acquire BIOVECTRA Inc from H.I.G. Capital</li> <li>BIOVECTRA is a CDMO producing active pharmaceutical ingredients and intermediates</li> <li>H.I.G. is a global alternative investment firm with \$65 billion of capital under management</li> <li>Agilent provides application focused solutions to the life sciences, diagnostics and applied chemical markets</li> <li>Total Consideration: \$925 million cash</li> </ul>
Healthcare Services	<p>Midwest Orthopedic and Musculoskeletal Alliance</p> <p>(Comprises 11 physician-owned entities)</p>		<ul style="list-style-type: none"> <li>Surgery Partners Inc. (NASDAQ: SGRY), a portfolio company of Bain Capital Public Equity, entered a definitive agreement to acquire 11 physician-owned entities to form Midwest Orthopedic and Musculoskeletal Alliance ("MOMA")</li> <li>MOMA comprises a hospital, two ASCs and a network of clinical sites providing general orthopedic care, joint replacement, sports medicine, physical therapy and interventional pain among other musculoskeletal services</li> <li>Surgery Partners is a healthcare services company that operates a network of surgical facilities and provides outpatient care across more than 180 locations in 32 states</li> <li>Bain is a private equity firm based in Boston managing \$185 billion assets; its investment mandate includes all healthcare sub-sectors</li> <li><b>A senior member of TM Capital's healthcare team led this transaction at a prior firm</b></li> </ul>

# HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.

LTM Stock Price Index



# SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
Northstar Switzerland SARL (Haleon plc (LSE: HLN))	Dr. Reddy's Laboratories Ltd (BOM: 500124)	Northstar Switzerland offers anti-smoking aids in lozenge, gum and patch form Total Consideration: \$660 million cash

Ironshore Pharmaceuticals Inc.	Collegium Pharmaceutical Inc (NAS: COLL)	Ironshore's lead product, Jornay PM, is a prescription central nervous system stimulant used for treatment of ADHD and the only stimulant medication that is administered in the evening Total Consideration: \$646 million cash
--------------------------------	--	---

Alimera Sciences Inc (NASD: ALIM)	ANI Pharmaceuticals Inc (NASD: ANIP)	Alimera is a pharmaceutical company developing and commercializing ophthalmology therapeutics including ILLUVIEN®, a treatment for diabetic macular edema Total Consideration: \$381 million cash Per Share Price Premium: 74.6%
-----------------------------------	--------------------------------------	--

Target	Acquiror	Life Sci / Diagnostics Transactions
--------	----------	-------------------------------------

Inventia Healthcare Limited's core Oral Solid Dosage (India Life Sciences Fund)	Platinum Equity Advisors LLC	Inventia supplies semi-finished and finished OSD formulations for both regular and value-added generics
---	------------------------------	---

QED Bioscience Inc (Genovis AB (STO: GENO))	Leinco Technologies Inc (Ampersand Capital Partners)	QED is a provider of antibodies, kits and recombinant proteins & antigens catering to the in-vitro diagnostics and research communities
---	--	---

Ansh Labs LLC	VION Biosciences LLC (Iron Path Capital LLC)	Ansh Labs develops and manufactures immunodiagnostic assays and reagents for research and diagnostics
---------------	--	---

Target	Acquiror	Health Services Transactions
Integrated Oncology Network LLC (Silver Oak Services Partners LLC)	Cardinal Health Inc (NYSE: CAH)	Integrated Oncology Network is a management, development and advisory firm providing services to physician groups and hospitals Total Consideration: \$1.1 billion cash

Physician Services Group LLC	Fulcrum Equity Partners Inc	Physician Services Group provides transitional and geriatric care for patients residing in skilled nursing and assisted living facilities throughout South Carolina
------------------------------	-----------------------------	---

Flourish Research Holdings, LLC (NMS Capital LLC)	Genstar Capital LLC	Flourish is a multi-site clinical trial organization focused on cardiovascular, metabolic, neuroscience and infectious disease therapeutic areas among others
---	---------------------	---

Target	Acquiror	Medical Device Transactions
--------	----------	-----------------------------

Asahi Kasei Medical Co. Ltd	Integral Co. Ltd (TKS: 5842)	Asahi Kasei Medical manufactures and develops products such as dialyzers, therapeutic apheresis products, leukocyte reduction filters and virus removal filters Total Consideration: \$393 million cash
-----------------------------	------------------------------	--


NeuroAdvanced Corp	Nihon Kohden Corp (TKS: 6849)	NeuroAdvanced develops and manufactures biphasic AEDs and defibrillators for hospital and ambulance use Total Consideration: \$108 million cash
--------------------	-------------------------------	--

Vapotherm Inc	Perceptive Advisors LLC; SLR Capital Partners LLC	Vapotherm is a medical technology business focused on non-invasive respiratory support
---------------	---	--

## Selected TM Capital Healthcare Experience




## TM Capital's Healthcare Industry Contacts




**James McLaren**  
Managing Director  
jmcclaren@tmcapital.com  
212.809.1414




**Michael Goldman**  
Managing Director  
mgoldman@tmcapital.com  
212.809.1419



**John Dean**  
Director  
jdean@tmcapital.com  
404.995.6234



**Paul Smolevitz**  
Managing Director  
psmolevitz@tmcapital.com  
212.809.1416



**Josh Mastracci**  
Director  
jmastracci@tmcapital.com  
404.924.4562



**Steve Hunter**  
Managing Director,  
Sponsor Coverage  
shunter@tmcapital.com  
404.995.6232

### ABOUT TM CAPITAL, A DIVISION OF JANNEY

FOUNDED IN 1989 AND NOW PART OF JANNEY MONTGOMERY SCOTT, TM CAPITAL IS THE CLIENT-FIRST INVESTMENT BANKING TEAM ADVISING INDUSTRY-LEADING COMPANIES ACROSS NORTH AMERICA AND AROUND THE WORLD. IN EVERYTHING WE DO, OUR PROFESSIONALS SHARE A RELENTLESS COMMITMENT TO ENGINEERING EXTRAORDINARY OUTCOMES WITH AN UNMATCHED STANDARD OF CLIENT CARE. OVER THE LAST THREE DECADES, WE HAVE COMPLETED NEARLY 450 TRANSACTIONS WITH A COMBINED VALUE OF \$30 BILLION. WITH OFFICES IN ATLANTA, BOSTON AND NEW YORK, OUR MISSION CRITICAL CAPABILITIES INCLUDE: COMPLEX MERGERS AND ACQUISITIONS; DEBT AND EQUITY FINANCINGS; MINORITY AND MAJORITY RECAPITALIZATIONS; RESTRUCTURINGS; AND BOARD ADVISORY SERVICES. TM CAPITAL IS ALSO A MEMBER OF OAKLINS, THE WORLD'S MOST EXPERIENCED MID-MARKET M&A ADVISOR, WITH OVER 850 PROFESSIONALS AND DEDICATED INDUSTRY TEAMS IN MORE THAN 45 COUNTRIES, HAVING CLOSED 1,700 TRANSACTIONS IN THE PAST FIVE YEARS. FOR MORE INFORMATION, PLEASE VISIT WWW.TMCAPITAL.COM.

### ABOUT JANNEY

JANNEY MONTGOMERY SCOTT LLC IS A LEADING FULL-SERVICE INVESTMENT BANKING AND FINANCIAL SERVICES FIRM SERVING INDIVIDUAL, CORPORATE, INSTITUTIONAL AND GOVERNMENT CLIENTS. JANNEY IS AN INDEPENDENTLY OPERATED SUBSIDIARY OF THE PENN MUTUAL LIFE INSURANCE COMPANY, ONE OF THE 15 LARGEST MUTUAL INSURANCE COMPANIES IN THE NATION, AND IS A MEMBER OF THE NEW YORK STOCK EXCHANGE, FINANCIAL INDUSTRY REGULATORY AUTHORITY AND THE SECURITIES INVESTOR PROTECTION CORPORATION.

THIS COMMUNICATION IS THE INTELLECTUAL PROPERTY OF TM CAPITAL, A DIVISION OF JANNEY AND MAY NOT BE REPRODUCED, DISTRIBUTED, OR PUBLISHED BY ANY PERSON FOR ANY PURPOSE WITHOUT JANNEY'S EXPRESS PRIOR CONSENT.

**DISCLAIMER:** This communication has been created by the Investment Banking Department of Janney Montgomery Scott LLC ("Janney") and is to be used for informational purposes only. It is not a product of Janney's Research Department. The information presented herein is taken from sources believed to be reliable but is not guaranteed by Janney as to its accuracy or completeness and is subject to change. The views expressed in this communication reflect the personal views of the author(s) regarding the subject securities and issuers and may differ with those of Janney or Janney's Research Department. This communication shall not constitute a solicitation or offer to purchase or sell a security. This communication is intended for Institutional Use Only, not for retail investors, and should not be distributed, forwarded, or otherwise disseminated. Nothing in this material should be construed as tax, legal, or accounting advice. Please consult your own tax, legal, and accounting professionals. Member: NYSE, FINRA, SIPC.